Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 14/20 | 0.45 |
| ▸ | CXCR1 | P25024 | 4/20 | 0.45 |
| ▸ | CASP3 | P42574 | 5/20 | 0.39 |
| ▸ | CASP7 | P55210 | 5/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137681 | 1.00 | CXCR2 (0.45) | CXCR2CXCR1CASP3CASP7NAMPT | |
| SCHEMBL7034500 | 1.00 | CXCR2 (0.45) | CXCR2CXCR1CASP3CASP7NAMPT | |
| SCHEMBL6564039 | 0.92 | CXCR2 (0.55) | CXCR2CXCR1 | |
| SCHEMBL7030872 | 0.89 | CXCR2 (0.51) | CXCR2 | |
| SCHEMBL6138226 | 0.89 | CXCR2 (0.51) | CXCR2 | |
| SCHEMBL2768897 | 0.87 | CXCR2 (0.43) | CXCR2CXCR1 | |
| SCHEMBL2768274 | 0.87 | CXCR2 (0.43) | CXCR2CXCR1 | |
| SCHEMBL2768276 | 0.87 | CXCR2 (0.43) | CXCR2CXCR1 | |
| SCHEMBL6563432 | 0.84 | CXCR2 (0.51) | CXCR2 | |
| SCHEMBL6564269 | 0.81 | CXCR2 (0.59) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261329-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | claimed |
| US-20030050298-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-03-13 | — | — | US | claimed |
| EP-1261329-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001068033-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-20 | — | — | WO | claimed |
| US-20030050298-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050298-A1 | Il-8 receptor antagonists | CXCL8, CCR8, IL1RN | CXCR2 10/4885CXCR1 12/4885CASP3 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.